UNSPSC 51171902: Famotidine

This classification denotes a histamine-2 receptor antagonist with the molecular formula C8H15N7O2S3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5QZO15J2Z8, chemically known as propanimidamide, n-(aminosulfonyl)-3-(((2-((diaminomethylene)amino)-4-thiazoly)methyl)thio)- but generally known as famotidine, which bears US NIH Compound Identifier 3325. European Medicines Agency schedules Famotidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07503MIG.

UNSPSC 51171902 Famotidine is a Commodity code that designates a specific pharmaceutical product — the histamine H2-receptor antagonist used primarily for acid reflux and ulcer management — but recent state and local procurement activity under this code shows minimal direct relevance to the code's nominal scope. The three most recent opportunities posted under or near this classification involve offender drug testing services (Collin County), a therapeutic pharmacy initiative exploring direct-to-manufacturer prescription contracting (Texas HHS Commission), and a multistate cooperative purchasing agreement for generic pharmaceuticals and OTC products (MMCAP). None of these solicitations target famotidine as a named line item; rather, they reflect broader pharmaceutical procurement, testing services, or supply-chain restructuring at the state and regional level. The code appears to see limited dedicated activity in state and local procurement.

Activity originates from Texas state agencies (HHS Commission), Texas counties (Collin County Community Supervision and Corrections Department), and multistate cooperative purchasing vehicles (MMCAP, which includes Minnesota and Oregon). The Collin County RFP for offender specimen collection and drug testing services, posted July 9, 2026 with a due date of July 23, 2026, carries an estimated contract value of $600,000 over two years with optional renewals, but targets testing methodologies and lab services rather than pharmaceutical products. The Texas HHS Commission's RFI posted April 3, 2026 solicits market intelligence on direct-to-manufacturer prescription programs without specifying budget or award values. MMCAP's RFP for generic multi-source pharmaceuticals and OTC products, posted January 20, 2026 with a due date of March 26, 2026, is the closest match to pharmaceutical procurement but does not isolate famotidine as a procurement target. The code shows little recent activity specifically tied to famotidine supply or acquisition by state and local governments.